Ensysce Biosciences News

10-Q: Quarterly report

SEC announcementMay 14 00:41 · Announcements

Ensysce Biosciences Q1 2024 GAAP EPS $(0.55) Beats $(0.90) Estimate, Sales $305.722K Miss $400.000K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.90) by 38.89 percent. The company reported quarterly sales of $305.72

BenzingaMay 13 20:27

Ensysce Biosciences Reports First Quarter 2024 Financial Results

Additionally, in January, the FDA's grant of Breakthrough Therapy designation for PF614-MPAR affirms belief in our novel approach to providing the ‘Next Generation' of opioid products.

AccesswireMay 13 20:02

Ensysce Biosciences' Presentation From the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Noble Capital Markets ("Noble") is a research-driven investment bank that has supported small and microcap companies since 1984.

AccesswireApr 19 20:01

Ensysce Biosciences Reports Q4 Results

Seeking AlphaMar 15 22:26

Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of

BenzingaMar 15 20:06

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.

AccesswireMar 15 20:02

Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)

Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice fro

BenzingaFeb 27 21:11

Ensysce Receives FDA Guidance on Opioid With Overdose Protection

InvestingFeb 21 21:40

Ensysce Biosciences Receives FDA Guidance For PF614-MPAR Program

The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of severe pain. The FDA provided helpful feedback and advice on non-clinical st

BenzingaFeb 21 21:06

Ensysce Biosciences Announces Successful Meeting With FDA for PF614-MPAR, a Next Generation Opioid With Overdose Protection

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, is providing an update following its recent meeting with the Food and Drug Administration (FDA) regarding its second product, a 'Next Generation' opioid analgesic with overdose protection, PF614-MPAR.

Ensysce BiosciencesFeb 21 21:00

Ensysce Biosciences Reports Promising PF614 Study Results

InvestingFeb 15 22:42

Ensysce Biosciences Secures Funding and Expands Shareholder Value

TipRanksFeb 15 06:42

Ensysce Biosciences Exercises Rights to Buy Shares at a Lower Price

InvestingFeb 13 21:24

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription dru

AccesswireFeb 13 21:00

TENX, PBM and PRSO Among Pre-market Losers

Seeking AlphaFeb 8 21:53

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

Ensysce Biosciences, Inc. (NASDAQ:ENSC) today announced they have been selected to present one of the top 12 best Flash Talks in the Trailblazer Session at the 2024 American Association of Pain Medicine (AAPM) Meeting on March 9th.

Ensysce BiosciencesFeb 6 21:00

Conmed, Relmada Therapeutics Among Healthcare Movers

Seeking AlphaFeb 1 23:00

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersTransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 17.2% to $0.81 during Wednesday's after-market session. Align Tech (NASDAQ:ALGN) shares increased by 13.29% to $302.86. The company'

BenzingaFeb 1 05:31

Theratechnologies, DocGo Among Healthcare Movers

Seeking AlphaJan 31 23:00